New Methodologies in the Molecular Monitoring of CML.

Abstract excerpt

In chronic myeloid leukemia (CML), the BCR-ABL fusion gene is both the therapeutic target of tyrosine kinase inhibitors and the indisputable direct marker of disease burden. Thus, sensitive assays for BCR-ABL now drive therapeutic options and are good surrogates for short- and long-term outcomes. Because CML is such an ideal model, new methods are arising that should make testing in CML faster, more reliable, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA
• Share to BCR gene
• Share to High-Throughput Nucleotide Sequencing